Acute Montelukast in Asthma

• Status: Completed
• Trial end date: 2004-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Patients presenting to hospital with an acute asthma exacerbation severe enough to require admission would receive full standard treatment according to British Thoracic Society guidelines in addition they would be offered the opportunity to take part in the study which would requite them to take a capsule of either montelukast or placebo.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of East Anglia
• Collaborators: Merck Sharp & Dohme Corp.; Norfolk Association of Asthma Nurses
• Treatments: Montelukast

Criteria

Inclusion Criteria:

• Acute Asthma exacerbation requiring hospitalisation

Exclusion Criteria:

• Smoking history greater than or equal to 10 pack years

• Presenting PEFR greater than or equal to 75% predicted / best

• Failure to demonstrate greater than or equal to 15% variability in PEFR or FEV during the study

• Any significant and active pulmonary pathology other than asthma

• Pregnancy or breastfeeding

• Intended pregnancy or inability to take adequate precautions against conception

• Patient already on Montelukast

• Patient already on Phenobarbitone

• Patient already on Rifampicin

• Patient already on Phenytoin

• Chronic airflow limitation